Table 2.

Targeted therapies of phase 3 studies in SSc patients

Trial drug	Target	Inclusion criteria	Treatment	IS	Endpoints	Duration	Results
Nintedanib	Tyrosine kinase inhibitors (FGF, VEGF, PDGF)	SSc-ILD  HRCT ≥ 10% Early (≤ 7 years)	150 mg twice a day	Yes	Annual rate of decline (FVC) mRSS SGRQ	52 weeks	Reduced FVC decline in nintedanib (p = 0.04) No change in mRSS or SGRQ
Tocilizumab	IL-6	Early (≤ 5 years) dcSSc (mRSS ≥ 10)	162 mg sc weekly	No	mRSS FVC	48 weeks	No significant change in mRSS (p = 0.098) Change in FVC favoured TCZ (p = 0.0015)

IS immunosuppressive treatment, SSc systemic sclerosis, ILD interstitial lung disease, HRCT high-resolution computed tomography, FVC forced vital capacity, SGRQ St. George’s Respiratory Questionnaire